GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (FRA:2MT0) » Definitions » Sale Of Investment

Athenex (FRA:2MT0) Sale Of Investment : €17.29 Mil (TTM As of Dec. 2022)


View and export this data going back to 2017. Start your Free Trial

What is Athenex Sale Of Investment?

Athenex's sale of investment for the three months ended in Dec. 2022 was €0.05 Mil. It means Athenex gained €0.05 Mil from selling investments. Athenex's sale of investment for the trailing twelve months (TTM) ended in Dec. 2022 was €17.29 Mil.

Compared with last quarter (€-0.35 Mil in Sep. 2022 ), Athenex gained more money from selling investments in Dec. 2022 (€0.05 Mil).

Athenex Sale Of Investment Historical Data

The historical data trend for Athenex's Sale Of Investment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athenex Sale Of Investment Chart

Athenex Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Sale Of Investment
Get a 7-Day Free Trial 59.53 89.18 46.32 174.88 17.64

Athenex Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Sale Of Investment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.62 8.62 8.98 -0.35 0.05

Athenex Sale Of Investment Calculation

Sale of Investments represents cash inflow on the sale of investments in securities.

Sale Of Investment for the trailing twelve months (TTM) ended in Dec. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €17.29 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Athenex Sale Of Investment Related Terms

Thank you for viewing the detailed overview of Athenex's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.

Athenex (FRA:2MT0) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Athenex Inc (FRA:2MT0) » Definitions » Sale Of Investment
Comparable Companies
LIFD CRYM SCYX RLBD BFRI GENH QLI UNRV AVDL ALID XTER:MRK ZTS TSE:4502 NSE:SUNPHARMA CTLT TSE:4507 SHSE:600196 SZSE:000538 VTRS NSE:DIVISLAB
Traded in Other Exchanges
N/A
Address
1001 Main Street, Suite 600, Conventus Building, Buffalo, NY, USA, 14203
Website
https://www.athenex.com
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Its current clinical pipeline is derived from Orascovery, based on a P-glycoprotein (P-gp) pump inhibitor, Src Kinase inhibition, T-cell receptor-engineered T-cells, and arginine deprivation therapy technology platforms. It is primarily engaged in conducting research and development activities through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting preclinical and clinical testing, recruiting personnel, identifying and evaluating additional drug candidates for potential in-licensing or acquisition, and raising capital to support development and commercialization activities.

Athenex (FRA:2MT0) Headlines

No Headlines